Larotrectinib is a potent (IC50s < 11 nM) inhibitor of tropomyosin receptor kinases A, B, and C (TrkA, B, and C).1 It is >100 fold selective against a panel of 229 kinases. Larotrectinib markedly attenuated bone cancer pain and significantly blocked the
* VAT and and shipping costs not included. Errors and price changes excepted